Prostate Cancer Diagnostic Market By Test Type (Tumor Biomarker Tests, Imaging, Biopsy, Other) By Cancer Stage (Stage I, Stage II A, Stage II B, Stage III, Stage IV), By End User (Hospital Associated Labs, Independent Diagnostic Labs, Diagnostic Imaging Centers, Cancer Research Institutes,Others) and Geography

Prostate Cancer Diagnostic Market size was valued at USD 126.5 billion in 2023 and is poised to grow at a CAGR of 8.6% from 2024 to 2030. Prostate cancer is the most common type of cancer in men it is characterized by the abnormal development of cells in the prostate gland and it may extend to the surrounding parts of the prostate gland. The prostate cancer diagnostics market is classified based on product type, age, cancer stage, and geography. Prostate cancer is age-dependent cancer risk of prostate cancer increases with an increase in age, family history, chemical exposure, smoking, inflammation of the prostate and infections are other risk factors for prostate cancer.

The prostate cancer diagnostic market is expected to show significant growth over the forecast period owing to the increasing prevalence of prostate cancer and technological advancements. The biopsy is expected to be the dominant diagnostic tool in prostate cancer diagnosis as it is mandatory to determine the presence of a cancerous lump and the cause of a high level of prostate-specific antigen (PSA). Imagining prostate cancer diagnosis is expected to rise in the forecasted period due to technological advances in imaging such as a newer approach to measuring blood flow within the gland using a technique called color Doppler ultrasound. It detects tumors more accurately. ConfirmMDx is an advanced diagnosis method which is a test that looks at certain genes in the cells from a prostate biopsy sample for accurate diagnosis. Multi-parametric MRI is a newer technique that can be used to help determine the extent of the cancer and how severe it might be.